Allspring Global Investments
QNCX icon

Allspring Global Investments’s Quince Therapeutics QNCX Stock Holding History

Allspring Global Investments’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-107
Closed -$28K – 2943
2022
Q3 		$28K Buy
107
+33
+45% +$12.6K ﹤0.01% 2543
2022
Q2 		$32K Sell
74
-2
-3% -$1.41K ﹤0.01% 2376
2022
Q1 		$93K Buy
76
+40
+111% +$54.4K ﹤0.01% 2765
2021
Q4 		$90K Buy
+36
New +$220K ﹤0.01% 2782

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Allspring Global Investments's QNCX Position: Q4 2022 in Review

Allspring Global Investments sold out of Quince Therapeutics (QNCX) in Q4 2022, closing a stake of 107 shares — an estimated $28K sold.

Allspring Global Investments first reported a position in QNCX in Q4 2021 and held it in 4 quarters. The position peaked at $93K in Q1 2022. 48 funds tracked by Wall St. Rank hold QNCX as of Q4 2022.

  • Allspring Global Investments reported no remaining Quince Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Allspring Global Investments sold 107 Quince Therapeutics shares in Q4 2022, an estimated $28K.
  • Allspring Global Investments first reported a position in Quince Therapeutics in Q4 2021 and held it in 4 quarters.
  • Allspring Global Investments's Quince Therapeutics position peaked at $93K in Q1 2022.
  • 48 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2022.

Based on Allspring Global Investments's 13F filing for Q4 2022, filed 23 Jan 2023.